Title : Sorafenib has potent antitumor activity against multiple myeloma in vitro, ex vivo, and in vivo in the 5T33MM mouse model.

Pub. Date : 2012 Oct 15

PMID : 22952216






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Mcl-1, a survival factor in multiple myeloma, is downregulated at the protein level by sorafenib allowing for the execution of cell death, as ectopic overexpression of this protein protects multiple myeloma cells. Sorafenib myeloid cell leukemia sequence 1 Mus musculus
2 Concomitant targeting of Mcl-1 by sorafenib and of Bcl-2/Bcl-xL by the antagonist ABT737 improves the efficacy of sorafenib in multiple myeloma cell lines and CD138(+)-enriched primary cells in the presence of bone marrow stromal cells. Sorafenib myeloid cell leukemia sequence 1 Mus musculus
3 Concomitant targeting of Mcl-1 by sorafenib and of Bcl-2/Bcl-xL by the antagonist ABT737 improves the efficacy of sorafenib in multiple myeloma cell lines and CD138(+)-enriched primary cells in the presence of bone marrow stromal cells. Sorafenib myeloid cell leukemia sequence 1 Mus musculus